Nanjing Pharmaceutical Group Company600713.SHValuation Analysis

As of Oct 19, 2026, Nanjing Pharmaceutical Group Company (600713.SH) trades at a P/E of 10.80x, P/B of 0.94x, P/S of 0.12x, and a dividend yield of 3.27%.
Longitudinal percentile comparison: P/E sits at the 20th percentile over the trailing 10Y window (vs. 39th percentile over 3Y); P/B sits at the 14th percentile over the trailing 10Y window (vs. 45th percentile over 3Y); P/S sits at the 40th percentile over the trailing 10Y window (vs. 73rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 2nd percentile within its industry and the 5th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.58%, ranking at the 97th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 6.0 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 3.27% comes from cash dividends, with an implied ~1.31% from buybacks — a fairly balanced mix of both channels. Nanjing Pharmaceutical Group Company operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.